A study by researchers at Case Western Reserve University examined 1.7 million diabetes patients in the U.S. and found that semaglutide, an ingredient in Ozempic, significantly lowers the risk of developing Alzheimer's disease. Given that type 2 diabetes is associated with higher dementia rates due to shared risk factors like obesity and impaired glucose metabolism, these findings highlight the potential benefits of semaglutide beyond diabetes management. The need for randomized clinical trials remains to confirm these associations and better understand the mechanisms involved.
Researchers found that semaglutide, the active ingredient in Ozempic, is linked to a reduced risk of Alzheimer's among diabetes patients.
Collection
[
|
...
]